½ÃÀ庸°í¼­
»óǰÄÚµå
1610269

¼¼°èÀÇ Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå : Ç÷§Æû, »ùÇÃ, ±¸¸Å, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Point of Care & Rapid Diagnostics Market by Platform (Dipstick, Immunoassay, Microfluidics), Sample (Blood, Urine), Purchase, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀº 2023³â¿¡ 484¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 518¾ï 5,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.11%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 783¾ï 4,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) ¹× ½Å¼Ó Áø´ÜÀº ȯÀÚÀÇ Ä¡·á ÇöÀå ¶Ç´Â ±× ±Ùó¿¡¼­ ¼öÇàµÇ´Â ÀÇ·á °Ë»ç¸¦ Æ÷ÇÔÇϸç, Áï°¢ÀûÀÎ ÀÓ»ó ÆÇ´ÜÀ» ¿ëÀÌÇϰÔÇϱâ À§ÇØ ½Å¼ÓÇÑ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´ÜÀÇ Çʿ伺Àº ƯÈ÷ ÀÀ±Þ ÀÇ·á, ½Ã°ñ ȯ°æ, À¯Ç༺ µî¿¡¼­ ȯÀÚÀÇ ´ë±â ½Ã°£À» ´ÜÃàÇÏ°í °á°ú¸¦ °³¼±Çϱâ À§ÇØ Å±¹ ¹«¸®ÇÑ Áø´ÜÀÌ ¿ä±¸µÇ°í ÀÖ´Â °Í¿¡ ±âÀÎÇÕ´Ï´Ù. POC ¹× ½Å¼Ó Áø´ÜÀÇ ¿ëµµ´Â Æ÷µµ´ç ¸ð´ÏÅ͸µÀ̳ª ÀӽŠ°Ë»ç·ÎºÎÅÍ, COVID-19¿Í °°Àº °¨¿°ÁõÀÇ °íµµ ºÐÀÚÁø´Ü±îÁö ´Ù¹æ¸é¿¡ °ÉĨ´Ï´Ù. º´¿ø, Áø·á¼Ò, ÀçÅÃÄ¡·á ȯ°æ, ¿¬±¸½Ç µî ´Ù¹æ¸é¿¡ °ÉÄ£ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â °ÍÀº ±â¼úÀÇ Áøº¸, ¸¸ ¼ºÁúȯ Áõ°¡, ÇコÄÉ¾î ¼­ºñ½ºÀÇ ºÐ»êÈ­¿¡ ´ëÇÑ ¼ö¿äÀÇ ³ô¾ÆÁüÀÔ´Ï´Ù. ¿ø°Ý ÀǷḦ È®ÀåÇϰí Áø´ÜÀ» µðÁöÅÐ °Ç°­ Ç÷§Æû°ú ÅëÇÕÇÏ°í ´õ ³ªÀº ȯÀÚ °ü¸®¸¦ À§ÇØ ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» °­È­ÇÏ´Â µ¥´Â ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. Àåºñ »óÈ£ ¿î¿ë¼º ¹× µ¥ÀÌÅÍ ÅëÇÕ°ú °°Àº ¿î¿µ»óÀÇ ¹®Á¦´Â ¿øÈ°ÇÑ º¸±ÞÀ» ¹æÇØÇÕ´Ï´Ù. ±â¼ú Çõ½ÅÀÇ ÁÖµÈ ºÐ¾ß·Î´Â ´ÙÇ׸ñ °Ë»ç ±â±âÀÇ °³¹ß, Áø´Ü Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ ÀΰøÁö´ÉÀÇ Å¾Àç, °¡Á¤¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ´Â ÈÞ´ëÇüÀÇ »ç¿ëÇϱ⠽¬¿î Ç÷§ÆûÀÇ °³¹ß µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. °³ÀÎÈ­ Äɾî¿Í ÇÁ·Î¾×Ƽºê °Ç°­ °ü¸®·ÎÀÇ ÀüȯÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¼ºÀåÀ» ¸ñÇ¥·ÎÇÏ´Â ±â¾÷Àº ¿¬±¸ °³¹ß Çù·Â¿¡ ÅõÀÚÇϰí, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î Æ÷Æ®Æú¸®¿À¸¦ ´Ù¾çÈ­Çϰí POC Áø´ÜÁ¦ÀÇ ÀåÁ¡°ú ¿Ã¹Ù¸¥ »ç¿ë¹ý¿¡ ´ëÇÑ °í°´ ±³À°À» ¼±È£ÇØ¾ß ÇÕ´Ï´Ù. ±×·¡¼­ ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ´õ¿í ³ô¿© Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ´Ù°í »ý°¢µË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 484¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 518¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 783¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 7.11%

½ÃÀå ¿ªÇÐ : ½Å¼ÓÇÏ°Ô ÁøÈ­ÇÏ´Â Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. °áÁ¤ÀÇ Á¤È­¿Í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °¨¿°ÁõÀÇ ±ÞÁõ
    • ºÐ»êÇü ÇコÄÉ¾î ½Ã½ºÅÛÀÇ º¸±Þ
    • Á¤ºÎÀÇ Áö¿ø Á¤Ã¥
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • »õ·Î¿î ½Å¼Ó Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÎÁöµµÀÇ ÀúÇÏ¿Í Ç¥ÁØÀûÀÎ ±ÔÁ¦ ¹æ¹ýÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • ´ÙÁßÈ­ ±â´ÉÀ» °®Ãá Çõ½ÅÀûÀÎ POC °Ë»ç
  • ½ÃÀåÀÇ °úÁ¦
    • °Ë»ç½Ç¿¡¼­ÀÇ È¿°úÀûÀÎ Áø´Ü ¹æ¹ýÀÇ ´ëü

Porter's Five Force : Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¿ì¸®´Â PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ» ³»´Ùº» Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» º¸¿©ÁÖ°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÃæºÐÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ÀÌ·ç±âÀ§ÇÑ ½Ã½ºÅÛÀ» ±¸Ãà ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °¨¿°ÁõÀÇ ¸¸¿¬·üÀÌ ³ô´Ù
      • ºÐ»êÇü ÇコÄÉ¾î ½Ã½ºÅÛÀÇ º¸±Þ
      • Á¤ºÎÀÇ Áö¿ø Á¤Ã¥
    • ¾ïÁ¦¿äÀÎ
      • »õ·Î¿î ½Å¼Ó Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÎÁöµµÀÇ ÀúÇÏ¿Í Ç¥ÁØÀûÀÎ ±ÔÁ¦ ¹æ¹ýÀÇ ºÎÁ·
    • ±âȸ
      • ´ÙÁßÈ­ ±â´ÉÀ» °®Ãá Çõ½ÅÀûÀÎ POC °Ë»ç
    • °úÁ¦
      • ½ÇÇè½Ç¿¡¼­ Áø´ÜÀ» ´ëüÇÏ´Â È¿°úÀûÀÎ ¹æ¹ý
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå : Ç÷§Æûº°

  • µö½ºÆ½
  • ¸é¿ª ÃøÁ¤
  • ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º

Á¦7Àå Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå : »ùÇú°

  • ÇÇ
  • ¼Òº¯

Á¦8Àå Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå : ±¸ÀÔº°

  • OTC
  • ó¹æÀü

Á¦9Àå Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø
  • ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ¹× ½Å¼Ó Áø´Ü ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Binx Health, inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Co-Diagnostics, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Genomadix Inc.
  • Lucira Health, Inc.
  • Meridian Bioscience Inc. by SD Biosensor
  • Novartis AG
  • OraSure Technologies, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
JHS 24.12.20

The Point of Care & Rapid Diagnostics Market was valued at USD 48.43 billion in 2023, expected to reach USD 51.85 billion in 2024, and is projected to grow at a CAGR of 7.11%, to USD 78.34 billion by 2030.

Point of Care (POC) and Rapid Diagnostics encompass medical testing conducted at or near the site of patient care, delivering quick results to facilitate immediate clinical decisions. The necessity for such diagnostics stems from the demand for timely diagnosis, especially in emergency care, rural settings, and during pandemics, to reduce patient wait times and improve outcomes. Applications of POC and rapid diagnostics range from glucose monitoring and pregnancy tests to advanced molecular diagnostics for infectious diseases like COVID-19. End-use sectors extend across hospitals, clinics, home care settings, and research laboratories. Market growth is fueled by technological advances, rising prevalence of chronic diseases, and an increasing demand for decentralizing healthcare services. The COVID-19 pandemic significantly expanded the need for rapid testing solutions, highlighting diagnostic speed as a pivotal factor. Opportunities lie in expanding telemedicine and integrating diagnostics with digital health platforms, enhancing real-time data analytics for better patient management. However, limitations such as the high cost of sophisticated POC devices, regulatory constraints, and variable accuracy compared to lab-based diagnostics pose challenges. Additionally, operational issues like device interoperability and data integration also hinder seamless adoption. Key areas for innovation include the development of multi-analyte testing devices, incorporating artificial intelligence for enhanced diagnostic accuracy, and advancing portable, user-friendly platforms for home use. The market is dynamic, reflecting a shift towards personalized care and proactive health management, demanding continuous innovation to address emerging healthcare needs. Companies looking to leverage growth should invest in R&D collaborations, diversify portfolio offerings with cost-effective solutions, and prioritize customer education on benefits and correct usage of POC diagnostics. Expanding access through partnerships with healthcare providers and exploring untapped regions would further cement market presence and drive sustainable growth.

KEY MARKET STATISTICS
Base Year [2023] USD 48.43 billion
Estimated Year [2024] USD 51.85 billion
Forecast Year [2030] USD 78.34 billion
CAGR (%) 7.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Point of Care & Rapid Diagnostics Market

The Point of Care & Rapid Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High oprevelance of the infectious diseases
    • Proliferation of decentralized healthcare systems
    • Supportive government policies
  • Market Restraints
    • Reduced awareness of new rapid diagnostic tests and lack of standard regulatory methods
  • Market Opportunities
    • Innovative POC test with multiplexing capabilities
  • Market Challenges
    • Alternate effective ways of diagnosis in laboratories

Porter's Five Forces: A Strategic Tool for Navigating the Point of Care & Rapid Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Point of Care & Rapid Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Point of Care & Rapid Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Point of Care & Rapid Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Point of Care & Rapid Diagnostics Market

A detailed market share analysis in the Point of Care & Rapid Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Point of Care & Rapid Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Point of Care & Rapid Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Point of Care & Rapid Diagnostics Market

A strategic analysis of the Point of Care & Rapid Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Point of Care & Rapid Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Binx Health, inc., bioMerieux SA, Cardinal Health, Inc., Co-Diagnostics, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Genomadix Inc., Lucira Health, Inc., Meridian Bioscience Inc. by SD Biosensor, Novartis AG, OraSure Technologies, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Point of Care & Rapid Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Platform, market is studied across Dipstick, Immunoassay, and Microfluidics.
  • Based on Sample, market is studied across Blood and Urine.
  • Based on Purchase, market is studied across OTC and Prescription.
  • Based on End-User, market is studied across Homecare, Hospital, and Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High oprevelance of the infectious diseases
      • 5.1.1.2. Proliferation of decentralized healthcare systems
      • 5.1.1.3. Supportive government policies
    • 5.1.2. Restraints
      • 5.1.2.1. Reduced awareness of new rapid diagnostic tests and lack of standard regulatory methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative POC test with multiplexing capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Alternate effective ways of diagnosis in laboratories
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Point of Care & Rapid Diagnostics Market, by Platform

  • 6.1. Introduction
  • 6.2. Dipstick
  • 6.3. Immunoassay
  • 6.4. Microfluidics

7. Point of Care & Rapid Diagnostics Market, by Sample

  • 7.1. Introduction
  • 7.2. Blood
  • 7.3. Urine

8. Point of Care & Rapid Diagnostics Market, by Purchase

  • 8.1. Introduction
  • 8.2. OTC
  • 8.3. Prescription

9. Point of Care & Rapid Diagnostics Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospital
  • 9.4. Pharmacy

10. Americas Point of Care & Rapid Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Point of Care & Rapid Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Point of Care & Rapid Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson and Company
  • 3. Binx Health, inc.
  • 4. bioMerieux SA
  • 5. Cardinal Health, Inc.
  • 6. Co-Diagnostics, Inc.
  • 7. Danaher Corporation
  • 8. F. Hoffmann-La Roche AG
  • 9. Genomadix Inc.
  • 10. Lucira Health, Inc.
  • 11. Meridian Bioscience Inc. by SD Biosensor
  • 12. Novartis AG
  • 13. OraSure Technologies, Inc.
  • 14. Siemens Healthineers AG
  • 15. Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦